About Heparin cofactor 2
Heparin cofactor 2 (SERPIND1) is a protein
from Homo sapiens identified by UniProt accession
P05546, 499 residues long.
MolForge cross-references it against 0 known binders and
183 disease associations.
Target properties
| Protein name | Heparin cofactor 2 |
| UniProt accession | P05546 |
| Gene | SERPIND1 |
| Organism | Homo sapiens |
| Length | 499 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (183)
Diseases linked to this target (Open Targets).
- heparin cofactor 2 deficiency · score 0.72
- Venous thrombosis · score 0.67
- hemorrhage · score 0.27
- neurodegenerative disease · score 0.26
- mean platelet volume · score 0.25
- cutaneous melanoma · score 0.23
- breast adenocarcinoma · score 0.21
- squamous cell lung carcinoma · score 0.20
- platelet component distribution width · score 0.20
- head and neck squamous cell carcinoma · score 0.15
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P05546-F1 | alphafold | PREDICTED | 79.65 | — |
Amino-acid sequence (499 residues)
MKHSLNALLI FLIITSAWGG SKGPLDQLEK GGETAQSADP QWEQLNNKNL SMPLLPADFH KENTVTNDWI PEGEEDDDYL DLEKIFSEDD DYIDIVDSLS VSPTDSDVSA GNILQLFHGK SRIQRLNILN AKFAFNLYRV LKDQVNTFDN IFIAPVGIST AMGMISLGLK GETHEQVHSI LHFKDFVNAS SKYEITTIHN LFRKLTHRLF RRNFGYTLRS VNDLYIQKQF PILLDFKTKV REYYFAEAQI ADFSDPAFIS KTNNHIMKLT KGLIKDALEN IDPATQMMIL NCIYFKGSWV NKFPVEMTHN HNFRLNEREV VKVSMMQTKG NFLAANDQEL DCDILQLEYV GGISMLIVVP HKMSGMKTLE AQLTPRVVER WQKSMTNRTR EVLLPKFKLE KNYNLVESLK LMGIRMLFDK NGNMAGISDQ RIAIDLFKHQ GTITVNEEGT QATTVTTVGF MPLSTQVRFT VDRPFLFLIY EHRTSCLLFM GRVANPSRS
Explore Heparin cofactor 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets